Novartis (NVS) announced on Friday that, following regulatory feedback, it has withdrawn its EU marketing application for Pluvicto, which aimed at broadening the use of the radiotherapy for a specific ...

The trial involves a PSMA-directed T cell engager using Janux’s tumour-activated platform to activate T cells.

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...

Talazoparib and enzalutamide combination reduces death risk by 20.4% in mCRPC patients, regardless of HRR status. The combination therapy offers survival benefits without increased toxicity, making it ...

HLD-0915, a RIPTACT therapeutic, targets mCRPC by linking the androgen receptor with an effector protein, disrupting cancer cell functions. The phase 1/2 trial will evaluate HLD-0915's safety, ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

Results suggest bone-protecting agents should be used in patients with metastatic castration-resistant prostate cancer and bone metastasis, especially in the era of androgen receptor pathway ...

Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux’s ...

The authors examine how insurer and patient out-of-pocket payments for advanced prostate cancer differ by drug and health plan type and describe the relationship between these payments and utilization ...

Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC) has changed considerably. Persistent androgen receptor (AR) signaling has been identified as a target for ...